1	EPOX	EPOX	B-NP	NN	B-protein	2	SUB	-1
2	inhibits	inhibit	B-VP	VBZ	O	0	ROOT	18	inhibits
3	angiogenesis	angiogenesis	B-NP	NN	O	2	OBJ	3	angiogenesis
4	by	by	B-PP	IN	O	2	VMOD	-1
5	degradation	degradation	B-NP	NN	O	4	PMOD	11	degradation
6	of	of	B-PP	IN	O	5	NMOD	-1
7	Mcl-1	Mcl-1	B-NP	NN	B-protein	6	PMOD	-1
8	through	through	B-PP	IN	O	2	VMOD	17	through
9	ERK	ERK	B-NP	NN	B-protein	10	NMOD	-1
10	inactivation	inactivation	I-NP	NN	O	8	PMOD	18	inactivation
11	.	.	O	.	O	2	P	-1

1	PURPOSE	PURPOSE	B-NP	NN	O	0	ROOT	-1
2	:	:	O	:	O	1	P	-1
3	Antiangiogenic	Antiangiogenic	B-NP	JJ	O	4	NMOD	3	angiogenic
4	therapy	therapy	I-NP	NN	O	5	SUB	18	therapy
5	is	be	B-VP	VBZ	O	1	NMOD	-1
6	considered	consider	I-VP	VBN	O	5	VC	-1
7	as	as	B-PP	IN	O	6	VMOD	-1
8	an	an	B-NP	DT	O	10	NMOD	-1
9	effective	effective	I-NP	JJ	O	10	NMOD	0
10	strategy	strategy	I-NP	NN	O	7	PMOD	-1
11	for	for	B-PP	IN	O	10	NMOD	-1
12	controlling	control	B-VP	VBG	O	11	PMOD	16	controlling
13	the	the	B-NP	DT	O	16	NMOD	-1
14	growth	growth	I-NP	NN	O	16	NMOD	4	growth
15	and	and	I-NP	CC	O	16	NMOD	-1
16	metastasis	metastasis	I-NP	NN	O	12	OBJ	14	metastasis
17	of	of	B-PP	IN	O	16	NMOD	-1
18	tumors	tumor	B-NP	NNS	O	17	PMOD	-1
19	.	.	O	.	O	1	P	-1

1	Among	Among	B-PP	IN	O	15	VMOD	-1
2	a	a	B-NP	DT	O	3	NMOD	-1
3	myriad	myriad	I-NP	NN	O	1	PMOD	-1
4	of	of	B-PP	IN	O	3	NMOD	-1
5	biological	biological	B-NP	JJ	O	6	NMOD	-1
6	activities	activity	I-NP	NNS	O	4	PMOD	0
7	described	describe	B-VP	VBN	O	6	NMOD	-1
8	for	for	B-PP	IN	O	7	VMOD	-1
9	xanthone	xanthone	B-NP	NN	O	10	NMOD	-1
10	derivatives	derivative	I-NP	NNS	O	8	PMOD	-1
11	,	,	O	,	O	15	P	-1
12	the	the	B-NP	DT	O	14	NMOD	-1
13	anticancer	anticancer	I-NP	JJ	O	14	NMOD	-1
14	activity	activity	I-NP	NN	O	15	SUB	18	activity
15	is	be	B-VP	VBZ	O	23	VMOD	-1
16	quite	quite	B-ADJP	RB	O	17	AMOD	-1
17	remarkable	remarkable	I-ADJP	JJ	O	15	PRD	-1
18	,	,	O	,	O	23	P	-1
19	but	but	O	CC	O	23	VMOD	-1
20	the	the	B-NP	DT	O	22	NMOD	-1
21	molecular	molecular	I-NP	JJ	O	22	NMOD	-1
22	mechanism	mechanism	I-NP	NN	O	23	SUB	0
23	is	be	B-VP	VBZ	O	0	ROOT	-1
24	not	not	I-VP	RB	O	23	VMOD	-1
25	clearly	clearly	I-VP	RB	O	23	VMOD	-1
26	resolved	resolve	I-VP	VBN	O	23	VC	-1
27	.	.	O	.	O	23	P	-1

1	In	In	B-PP	IN	O	7	VMOD	-1
2	the	the	B-NP	DT	O	4	NMOD	-1
3	present	present	I-NP	JJ	O	4	NMOD	0
4	study	study	I-NP	NN	O	1	PMOD	-1
5	,	,	O	,	O	7	P	-1
6	we	we	B-NP	PRP	O	7	SUB	-1
7	investigated	investigate	B-VP	VBD	O	0	ROOT	-1
8	the	the	B-NP	DT	O	10	NMOD	-1
9	antiangiogenic	antiangiogenic	I-NP	JJ	O	10	NMOD	3	angiogenic
10	mechanism	mechanism	I-NP	NN	O	7	OBJ	18	mechanism
11	of	of	B-PP	IN	O	10	NMOD	-1
12	3	3	B-NP	CD	O	27	NMOD	-1
13	,	,	O	,	O	27	P	-1
14	6-di	6-di	B-NP	NNS	O	27	NMOD	-1
15	(	(	O	(	O	23	DEP	-1
16	2	2	B-NP	CD	O	20	NMOD	-1
17	,	,	O	,	O	20	P	-1
18	3-epoxypropoxy	3-epoxypropoxy	B-ADJP	JJ	O	20	NMOD	-1
19	)	)	O	)	O	20	NMOD	-1
20	xanthone	xanthone	B-NP	NN	O	23	DEP	-1
21	(	(	O	(	O	23	DEP	-1
22	EPOX	EPOX	B-NP	NN	B-protein	23	DEP	-1
23	)	)	O	)	O	14	NMOD	-1
24	,	,	O	,	O	27	P	-1
25	a	a	B-NP	DT	O	27	NMOD	-1
26	novel	novel	I-NP	JJ	O	27	NMOD	-1
27	Mcl-1	Mcl-1	I-NP	NN	B-protein	29	NMOD	-1
28	targeting	target	B-VP	VBG	O	29	NMOD	16	targeting
29	drug	drug	B-NP	NN	O	11	PMOD	-1
30	.	.	O	.	O	7	P	-1

1	EXPERIMENTAL	EXPERIMENTAL	B-NP	JJ	O	2	NMOD	-1
2	DESIGN	DESIGN	I-NP	NN	O	13	SUB	-1
3	:	:	O	:	O	2	P	-1
4	To	To	B-VP	TO	O	5	VMOD	-1
5	evaluate	evaluate	I-VP	VB	O	2	NMOD	-1
6	the	the	B-NP	DT	O	8	NMOD	-1
7	antiangiogenic	antiangiogenic	I-NP	JJ	O	8	NMOD	3	angiogenic
8	activity	activity	I-NP	NN	O	5	OBJ	18	activity
9	of	of	B-PP	IN	O	8	NMOD	-1
10	EPOX	EPOX	B-NP	NN	B-protein	9	PMOD	-1
11	,	,	O	,	O	13	P	-1
12	we	we	B-NP	PRP	O	13	SUB	-1
13	did	do	B-VP	VBD	O	0	ROOT	-1
14	cell	cell	B-NP	NN	O	15	NMOD	-1
15	viability	viability	I-NP	NN	O	22	NMOD	-1
16	,	,	O	,	O	22	P	-1
17	cell	cell	B-NP	NN	O	18	NMOD	-1
18	cycle	cycle	I-NP	NN	O	22	NMOD	0
19	,	,	O	,	O	22	P	-1
20	tube	tube	B-NP	NN	O	22	NMOD	-1
21	formation	formation	I-NP	NN	O	22	NMOD	2	formation
22	assay	assay	I-NP	NN	O	13	OBJ	-1
23	in	in	B-ADVP	FW	O	13	VMOD	-1
24	vitro	vitro	I-ADVP	FW	O	23	AMOD	-1
25	,	,	O	,	O	29	P	-1
26	and	and	O	CC	O	29	NMOD	-1
27	Matrigel	Matrigel	B-NP	NNP	O	29	NMOD	-1
28	plug	plug	I-NP	NN	O	29	NMOD	-1
29	assay	assay	I-NP	NN	O	13	OBJ	-1
30	in	in	B-ADVP	FW	O	13	VMOD	-1
31	vivo	vivo	I-ADVP	FW	O	30	AMOD	-1
32	.	.	O	.	O	13	P	-1

1	To	To	B-VP	TO	O	2	VMOD	-1
2	evaluate	evaluate	I-VP	VB	O	14	VMOD	-1
3	the	the	B-NP	DT	O	4	NMOD	-1
4	effect	effect	I-NP	NN	O	2	OBJ	16	effect
5	of	of	B-PP	IN	O	4	NMOD	-1
6	EPOX	EPOX	B-NP	NN	B-protein	5	PMOD	-1
7	on	on	B-PP	IN	O	4	NMOD	-1
8	the	the	B-NP	DT	O	11	NMOD	-1
9	endothelial	endothelial	I-NP	JJ	O	11	NMOD	-1
10	signaling	signaling	I-NP	NN	O	11	NMOD	0
11	pathway	pathway	I-NP	NN	O	7	PMOD	0
12	,	,	O	,	O	14	P	-1
13	we	we	B-NP	PRP	O	14	SUB	-1
14	did	do	B-VP	VBD	O	0	ROOT	-1
15	immunoblotting	immunoblotting	B-NP	NN	O	21	NMOD	-1
16	,	,	O	,	O	21	P	-1
17	immunoprecipitation	immunoprecipitation	B-NP	NN	O	21	NMOD	-1
18	,	,	O	,	O	21	P	-1
19	and	and	O	CC	O	21	NMOD	-1
20	immunofluorescence	immunofluorescence	B-NP	NN	O	21	NMOD	-1
21	analysis	analysis	I-NP	NN	O	14	OBJ	-1
22	.	.	O	.	O	14	P	-1

1	Intracellular	Intracellular	B-NP	JJ	O	3	NMOD	-1
2	glutathione	glutathione	I-NP	NN	O	3	NMOD	-1
3	levels	level	I-NP	NNS	O	4	SUB	-1
4	were	be	B-VP	VBD	O	0	ROOT	-1
5	determined	determine	I-VP	VBN	O	4	VC	-1
6	with	with	B-PP	IN	O	5	VMOD	-1
7	the	the	B-NP	DT	O	8	NMOD	-1
8	use	use	I-NP	NN	O	6	PMOD	0
9	of	of	B-PP	IN	O	8	NMOD	-1
10	monochlorobimane	monochlorobimane	B-NP	NN	O	14	NMOD	-1
11	,	,	O	,	O	14	P	-1
12	a	a	B-NP	DT	O	14	NMOD	-1
13	glutathione-specific	glutathione-specific	I-NP	JJ	B-DNA	14	NMOD	-1
14	probe	probe	I-NP	NN	I-DNA	9	PMOD	-1
15	.	.	O	.	O	4	P	-1

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT	0
2	:	:	O	:	O	1	P	-1
3	EPOX	EPOX	B-NP	NN	B-protein	6	NMOD	-1
4	induced	induce	B-VP	VBD	O	3	AMOD	17	induced
5	endothelial	endothelial	B-NP	JJ	B-cell_type	6	NMOD	-1
6	cell	cell	I-NP	NN	I-cell_type	7	NMOD	-1
7	apoptosis	apoptosis	I-NP	NN	O	1	NMOD	5	apoptosis
8	in	in	B-PP	IN	O	7	NMOD	-1
9	association	association	B-NP	NN	O	8	PMOD	16	association
10	with	with	B-PP	IN	O	9	NMOD	-1
11	proteasome-dependent	proteasome-dependent	B-NP	JJ	O	13	NMOD	17	dependent
12	Mcl-1	Mcl-1	I-NP	NN	B-protein	13	NMOD	-1
13	degradation	degradation	I-NP	NN	O	10	PMOD	11	degradation
14	.	.	O	.	O	1	P	-1

1	Down-regulation	Down-regulation	B-NP	NN	O	4	SUB	18	Down-regulation
2	of	of	B-PP	IN	O	1	NMOD	-1
3	Mcl-1	Mcl-1	B-NP	NN	B-protein	2	PMOD	-1
4	resulted	result	B-VP	VBD	O	0	ROOT	17	resulted
5	in	in	B-PP	IN	O	4	VMOD	-1
6	an	an	B-NP	DT	O	7	NMOD	-1
7	increase	increase	I-NP	NN	O	12	NMOD	17	increase
8	in	in	B-PP	IN	O	7	NMOD	-1
9	Mcl-1-free	Mcl-1-free	B-NP	JJ	O	10	NMOD	16	free
10	Bim	Bim	I-NP	NN	O	8	PMOD	-1
11	,	,	O	,	O	12	P	-1
12	activation	activation	B-NP	NN	O	5	PMOD	17	activation
13	of	of	B-PP	IN	O	12	NMOD	-1
14	Bax	Bax	B-NP	NN	B-protein	13	PMOD	-1
15	,	,	O	,	O	12	NMOD	-1
16	and	and	O	CC	O	15	PMOD	-1
17	then	then	O	RB	O	16	DEP	-1
18	signaling	signaling	B-NP	NN	O	17	PMOD	0
19	of	of	B-PP	IN	O	18	NMOD	-1
20	mitochondria-mediated	mitochondria-mediated	B-NP	JJ	O	21	NMOD	-1
21	apoptosis	apoptosis	I-NP	NN	O	19	PMOD	0
22	.	.	O	.	O	4	P	-1

1	Additionally	Additionally	B-ADVP	RB	O	13	VMOD	-1
2	,	,	O	,	O	13	P	-1
3	glutathione	glutathione	B-NP	NN	O	4	NMOD	-1
4	depletion	depletion	I-NP	NN	O	8	NMOD	18	depletion
5	and	and	O	CC	O	8	NMOD	-1
6	extracellular	extracellular	B-NP	JJ	B-protein	8	NMOD	-1
7	signal-regulated	signal-regulated	I-NP	JJ	I-protein	8	NMOD	-1
8	kinase	kinase	I-NP	NN	I-protein	12	NMOD	-1
9	(	(	O	(	O	11	DEP	-1
10	ERK	ERK	B-NP	NN	B-protein	11	DEP	-1
11	)	)	O	)	O	8	NMOD	-1
12	inactivation	inactivation	B-NP	NN	O	13	SUB	18	inactivation
13	was	be	B-VP	VBD	O	0	ROOT	-1
14	observed	observe	I-VP	VBN	O	13	VC	0
15	in	in	B-PP	IN	O	14	VMOD	-1
16	EPOX-treated	EPOX-treated	B-NP	JJ	B-cell_line	17	NMOD	19	treated
17	cells	cell	I-NP	NNS	I-cell_line	15	PMOD	-1
18	.	.	O	.	O	13	P	-1

1	Glutathione	Glutathione	B-NP	NN	O	2	NMOD	-1
2	supplementation	supplementation	I-NP	NN	O	3	SUB	19	supplementation
3	reversed	reverse	B-VP	VBD	O	0	ROOT	18	reversed
4	the	the	B-NP	DT	O	6	NMOD	-1
5	inhibitory	inhibitory	I-NP	JJ	O	6	NMOD	0
6	effects	effect	I-NP	NNS	O	3	OBJ	0
7	of	of	B-PP	IN	O	6	NMOD	-1
8	EPOX	EPOX	B-NP	NN	B-protein	7	PMOD	-1
9	on	on	B-PP	IN	O	6	NMOD	-1
10	ERK	ERK	B-NP	NN	B-protein	9	PMOD	-1
11	,	,	O	,	O	10	P	-1
12	which	which	B-NP	WDT	O	10	NMOD	-1
13	increases	increase	B-VP	VBZ	O	12	SBAR	17	increases
14	the	the	B-NP	DT	O	15	NMOD	-1
15	phosphorylation	phosphorylation	I-NP	NN	O	13	OBJ	12	phosphorylation
16	of	of	B-PP	IN	O	15	NMOD	-1
17	Mcl-1	Mcl-1	B-NP	NN	B-protein	16	PMOD	-1
18	at	at	B-PP	IN	O	15	NMOD	-1
19	T	T	B-NP	NN	O	23	NMOD	-1
20	(	(	B-LST	(	O	21	DEP	-1
21	163.	163.	I-LST	LS	O	23	NMOD	-1
22	)	)	O	)	O	21	DEP	-1
23	Overexpression	Overexpression	B-NP	NN	O	18	PMOD	9	Overexpression
24	of	of	B-PP	IN	O	23	NMOD	-1
25	mitogen-activated	mitogen-activated	B-NP	JJ	B-protein	27	NMOD	-1
26	protein/ERK	protein/ERK	I-NP	NN	I-protein	27	NMOD	-1
27	kinase	kinase	I-NP	NN	I-protein	24	PMOD	-1
28	(	(	O	(	O	30	DEP	-1
29	MEK	MEK	B-NP	NN	B-protein	30	DEP	-1
30	)	)	O	)	O	27	NMOD	-1
31	partially	partially	B-ADVP	RB	O	3	VMOD	-1
32	reversed	reverse	B-VP	VBD	O	3	VMOD	18	reversed
33	the	the	B-NP	DT	O	34	NMOD	-1
34	effect	effect	I-NP	NN	O	32	OBJ	16	effect
35	of	of	B-PP	IN	O	34	NMOD	-1
36	EPOX	EPOX	B-NP	NN	B-protein	35	PMOD	-1
37	on	on	B-PP	IN	O	34	NMOD	-1
38	Mcl-1	Mcl-1	B-NP	NN	B-protein	39	NMOD	-1
39	dephosphorylation	dephosphorylation	I-NP	NN	O	44	NMOD	13	dephosphorylation
40	,	,	O	,	O	44	P	-1
41	ubiquitination	ubiquitination	B-NP	NN	O	44	NMOD	0
42	,	,	O	,	O	44	P	-1
43	and	and	O	CC	O	44	NMOD	-1
44	degradation	degradation	B-NP	NN	O	37	PMOD	11	degradation
45	,	,	O	,	O	3	P	-1
46	further	further	B-ADVP	RB	O	47	VMOD	-1
47	implicating	implicate	B-VP	VBG	O	3	VMOD	-1
48	ERK	ERK	B-NP	NN	B-protein	47	OBJ	-1
49	in	in	B-PP	IN	O	47	VMOD	-1
50	the	the	B-NP	DT	O	51	NMOD	-1
51	regulation	regulation	I-NP	NN	O	49	PMOD	16	regulation
52	of	of	B-PP	IN	O	51	NMOD	-1
53	Mcl-1	Mcl-1	B-NP	NN	B-protein	54	NMOD	-1
54	stability	stability	I-NP	NN	O	52	PMOD	-1
55	.	.	O	.	O	3	P	-1

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT	-1
2	:	:	O	:	O	1	P	-1
3	This	This	B-NP	DT	O	4	NMOD	-1
4	study	study	I-NP	NN	O	5	SUB	-1
5	provides	provide	B-VP	VBZ	O	1	NMOD	-1
6	evidence	evidence	B-NP	NN	O	5	OBJ	-1
7	that	that	B-SBAR	IN	O	6	NMOD	-1
8	EPOX	EPOX	B-NP	NN	B-protein	9	SUB	-1
9	induces	induce	B-VP	VBZ	O	7	SBAR	17	induces
10	glutathione	glutathione	B-NP	NN	O	11	NMOD	-1
11	depletion	depletion	I-NP	NN	O	18	NMOD	18	depletion
12	,	,	O	,	O	18	P	-1
13	ERK	ERK	B-NP	NN	B-protein	14	NMOD	-1
14	inactivation	inactivation	I-NP	NN	O	18	NMOD	18	inactivation
15	,	,	O	,	O	18	P	-1
16	and	and	O	CC	O	18	NMOD	-1
17	Mcl-1	Mcl-1	B-NP	NN	B-protein	18	NMOD	-1
18	degradation	degradation	I-NP	NN	O	9	OBJ	11	degradation
19	on	on	B-PP	IN	O	18	NMOD	-1
20	endothelial	endothelial	B-NP	JJ	B-cell_type	21	NMOD	-1
21	cells	cell	I-NP	NNS	I-cell_type	19	PMOD	-1
22	,	,	O	,	O	18	P	-1
23	which	which	B-NP	WDT	O	18	NMOD	-1
24	leads	lead	B-VP	VBZ	O	23	SBAR	17	leads
25	to	to	B-PP	TO	O	24	VMOD	-1
26	inhibition	inhibition	B-NP	NN	O	25	PMOD	18	inhibition
27	of	of	B-PP	IN	O	26	NMOD	-1
28	angiogenesis	angiogenesis	B-NP	NN	O	27	PMOD	3	angiogenesis
29	.	.	O	.	O	1	P	-1

1	Our	Our	B-NP	PRP$	O	2	NMOD	-1
2	results	result	I-NP	NNS	O	3	SUB	0
3	suggest	suggest	B-VP	VBP	O	0	ROOT	-1
4	that	that	B-SBAR	IN	O	3	VMOD	-1
5	EPOX	EPOX	B-NP	NN	B-protein	6	SUB	-1
6	is	be	B-VP	VBZ	O	4	SBAR	-1
7	a	a	B-NP	DT	O	10	NMOD	-1
8	novel	novel	I-NP	JJ	O	10	NMOD	-1
9	antiangiogenic	antiangiogenic	I-NP	JJ	O	10	NMOD	3	angiogenic
10	agent	agent	I-NP	NN	O	6	PRD	-1
11	,	,	O	,	O	6	P	-1
12	making	make	B-VP	VBG	O	17	VMOD	-1
13	it	it	B-NP	PRP	O	17	SUB	-1
14	a	a	B-NP	DT	O	17	NMOD	-1
15	promising	promising	I-NP	JJ	O	17	NMOD	-1
16	lead	lead	I-NP	NN	O	17	NMOD	0
17	compound	compound	I-NP	NN	O	6	PRD	-1
18	for	for	B-PP	IN	O	17	NMOD	-1
19	further	further	B-NP	JJ	O	20	NMOD	-1
20	development	development	I-NP	NN	O	18	PMOD	0
21	in	in	B-PP	IN	O	17	NMOD	-1
22	the	the	B-NP	DT	O	23	NMOD	-1
23	treatment	treatment	I-NP	NN	O	21	PMOD	0
24	of	of	B-PP	IN	O	23	NMOD	-1
25	angiogenesis-related	angiogenesis-related	B-NP	JJ	O	26	NMOD	3	angiogenesis
26	pathologies	pathology	I-NP	NNS	O	24	PMOD	-1
27	.	.	O	.	O	3	P	-1

